With the end of the disclosure of the first quarterly report, the latest layout trend of 10 billion private placement surfaced. In the first quarter of this year, the 10 billion private investment, which used to be good at innovation and quite low-key, built a position against the market, with a 100 billion vaccine leader Chongqing Zhifei Biological Products Co.Ltd(300122) , with a market value of nearly 3 billion, which attracted market attention.
You should know that although this private placement appeared in the top ten circulating shareholders of more than 40 listed companies at the end of the first quarter, most of the stock market value did not exceed 100 million yuan. Yingshui investment has made a lot of money in the past few years, but it is not easy to invest in new shares this year. It bought Chongqing Zhifei Biological Products Co.Ltd(300122) . Let’s have a look at the layout intention in the first quarterp align=”center” style=”text-align:left;”> Chongqing Zhifei Biological Products Co.Ltd(300122) this year’s decline is more than 24% p align = “center” style = “text align: left;” Yingshui investment of nearly 3 billion, adding positions against the trend
Chongqing Zhifei Biological Products Co.Ltd(300122) disclosed the first quarter report of 2022, which showed that two products of 10 billion private Yingshui investment were listed as the top ten circulating shareholders of the company in the first quarter. Yingshui Heli No. 13 private equity fund and Yingshui Heli No. 9 private equity fund bought a total of 21.683 million shares, with a market value of 2.992 billion yuan at the end of the period. The China EU medical and health mixed fund managed by star fund manager Glenn also increased Chongqing Zhifei Biological Products Co.Ltd(300122) 458700 shares, increasing the number of shares to 15.042 million shares, with a market value of 2.071 billion yuan at the end of the period.
Yingshui investment, founded in June 2015, has risen rapidly in the past few years by seizing the new market opportunities of science and innovation board and gem, and has grown into a 10 billion private placement institution in Shanghai. Lu Gaowen, its leader, worked in CICC for two and a half years. Later, he served as the investment consultant of the investment department of Shanghai Tuofeng trading company. In 2015, he founded Shanghai Yingshui investment and served as the general manager. At present, Yingshui investment has 41 employees.
By the end of April this year, Yingshui investment had filed 469 private placement products with the fund industry association, and its investment layout in A-Shares was quite scattered. At the end of the first quarter of this year, Yingshui entered many of the top ten circulating shareholders of listed companies, but most of them held less than 100 million stock market value. Now we have bought Chongqing Zhifei Biological Products Co.Ltd(300122) nearly 3 billion in one breath. Let’s have a look at the layout intention.
Chongqing Zhifei Biological Products Co.Ltd(300122) is a star company with a market value of 100 billion on the gem. It is an international and whole industry chain high-tech biopharmaceutical enterprise integrating vaccine and biological products R & D, production, sales, distribution, import and export. The covid-19 vaccine developed by it has been the most discussed in the market in the past few years. Therefore, the company has also attracted the attention of institutional investors and used to be a big bull stock.
However, Chongqing Zhifei Biological Products Co.Ltd(300122) in the past year or so, the share price has been falling endlessly. As of the closing on April 29, Chongqing Zhifei Biological Products Co.Ltd(300122) closed at 94.50 yuan / share, down more than half from the high of 230 yuan in May last year, with the latest total market value of 151.2 billion yuan. Yingshui investment increased its position against the market and “copied the bottom” in the first quarter of this year.
From the performance of this year, Chongqing Zhifei Biological Products Co.Ltd(300122) fell by 24.16%. On April 14, the market heard the news that “one shot of HPV vaccine recommended by who is enough”. On that day, the share price of Chongqing Zhifei Biological Products Co.Ltd(300122) plummeted by 14.19%, which is the exclusive agent of MSD HPV vaccine in Chinap align=”center” style=”text-align:left;”> Double the net profit in the quarter self research and agent vaccine business is developing rapidly
According to the information of the annual report and the first quarterly report now disclosed, let’s take a look at the fundamentals of Chongqing Zhifei Biological Products Co.Ltd(300122) .
According to the annual report of 2021, Chongqing Zhifei Biological Products Co.Ltd(300122) achieved an operating revenue of 30.652 billion yuan, a year-on-year increase of 101.79%; The net profit attributable to the parent company was 10.209 billion yuan, a year-on-year increase of 209.23%; The basic earnings per share is 6.38 yuan, and it is proposed to distribute a cash dividend of 6 yuan (including tax) for every 10 shares to all shareholders.
Chongqing Zhifei Biological Products Co.Ltd(300122) 2021 R & D investment exceeded 800 million yuan, with a year-on-year increase of 69.38%. There are 29 independent R & D projects; The number of R & D personnel increased from 414 in 2020 to 566, a year-on-year increase of 36.71%. The company’s recombinant covid-19 vaccine was approved for conditional listing in 2022 and served as a sequential booster, providing protection to more than 100 million people. According to the securities times, the Institute of Microbiology of the Chinese Academy of Sciences and Chongqing Zhifei Biological Products Co.Ltd(300122) are also promoting the research and development of a new generation of recombinant protein covid-19 vaccine for the mutant strain, which is currently in the preclinical research stage.
The annual report also shows that Chongqing Zhifei Biological Products Co.Ltd(300122) as the exclusive agent of MSD HPV vaccine in Chinese Mainland, in 2021, the annual batch issuance volume of nine valent and four valent HPV vaccines was 10206200 and 8802500 respectively, with a year-on-year increase of 101.45% and 21.93%.
The first quarter report of 2022 also shows that Chongqing Zhifei Biological Products Co.Ltd(300122) achieved an operating revenue of 8.841 billion yuan in the first quarter, with a year-on-year increase of 125.16%; The net profit attributable to the parent company was 1.923 billion yuan, a year-on-year increase of 104.95%. In view of the significant increase in operating revenue, the company said that it was mainly due to the continuous growth of sales in the current period.
According to the first quarterly report of the company, the cooperation between Chongqing Zhifei Biological Products Co.Ltd(300122) and MSD is in normal progress. In the first quarter of this year, the number of batches issued by the company’s agent products increased significantly compared with the same period of last year, with the batch issuance of 2.11 million tetravalent HPV vaccines, an increase of nearly 70%; Nine valent HPV vaccines were issued in batches of 4.83 million, an increase of nearly 280%; 3.24 million pentavalent rotavirus vaccines were issued in batches, an increase of nearly 220%; 48 Shenzhen Universe (Group) Co.Ltd(000023) valent pneumonia vaccines were issued in batches, an increase of more than 100%.
China Merchants Securities Co.Ltd(600999) believes that the revenue side, covid-19 vaccine revenue of Chongqing Zhifei Biological Products Co.Ltd(300122) in 21 years is bright, and the routine vaccine business continues to grow at a high speed. On the profit side, covid-19 vaccine increased the profit of 21 years, and the profit growth of 22q1 was led by conventional vaccine. The company realized a net profit of 10.18 billion yuan in 2021, including 5.58 billion yuan of zhifeilong Kema net profit. “Agent + self research” double wheel drive, and the pipeline under research is advancing smoothly.
The penetration rate of HPV vaccine in China is still at a low level, which is expected to remain in short supply in the short term, and the agency business of the company is expected to continue to maintain rapid growth. At the same time, the company’s self-developed business also has a focus, and six product matrices have been formed, and “EC + micro card” is expected to take the lead in large-scale production. In the pipeline under research, three products have entered phase III clinic and two products have entered phase I clinic. While the pipeline is advancing smoothly, mRNA and other new technology platforms are laid to lay a solid foundation for future growthp align=”center” style=”text-align:left;”> Yingshui investment appeared in the first quarter p align = “center” style = “text align: left;” top 10 listed companies
Fund Jun found that as of the end of the first quarter of this year, the products of Yingshui investment appeared in the list of the top ten circulating shareholders of more than 40 listed companies, but most of them did not hold more than 100 million stock market value, and only Chongqing Zhifei Biological Products Co.Ltd(300122) , Jiangsu Eastern Shenghong Co.Ltd(000301) , Anhui Yingjia Distillery Co.Ltd(603198) , Sansure Biotech Inc(688289) , Zhongshan Broad-Ocean Motor Co.Ltd(002249) , Changying Xinzhi Technology Co.Ltd(002664) .
Zhongshan Broad-Ocean Motor Co.Ltd(002249) ‘s quarterly data show that Yingshui Yueyi No. 17 private equity fund under Yingshui investment reduced its holdings of 2.475 million shares in the first quarter of this year, and the number of shares held at the end of the period decreased to 268078 million shares, with a market value of 163 million yuan.
Meanwhile, Yingshui Zhengdong No. 2 private equity fund under Yingshui investment holds Jiangsu Eastern Shenghong Co.Ltd(000301) 34565600 shares, with a market value of 491 million yuan at the end of the period, which is unchanged from the end of last year.
The total market value of Yingshui Huijin and Yingshui Huijin’s private equity fund remained unchanged at the end of the period, and Yingshui Huijin’s private equity fund held a total of .
The overall market trend of this year was volatile, and the performance of new shares was also poor. According to wind data, as of April 29, 122 new shares had been issued this year, of which 36 new shares were broken on the first day of listing, with the proportion of broken individual shares reaching 29.51%. Among them, 10 companies fell by more than 20% on the first day.
Insiders told fund Jun that private equity funds such as Yingshui investment, which used to rely on new development and rapid growth in scale, are also strengthening the research and investment layout of subjective bull strategy and seeking transformation, because now, the new outlet has passed and it is impossible to follow the original path.
